Myofascial pain Musculoskeletal Diseases
Conditions
Interventions
The study is based on several separate protocols, and participants were randomly assigned to several groups. Group assignment was achieved by simple 1:1 randomization using a random sequence generated
Sponsors
Centrum Medyczne Provita
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Randomly selected healthy volunteers without active myofascial pain aged 18 to 70 years 2. Randomly selected volunteers aged 18-70 years with confirmed acute myofascial pain (latent and active myofascial trigger points - MTrPs) according to the MTrPs diagnostic criteria (Kietrys, D. M. et al. 2013, J. Sanchez et al. 2018) 3. Randomly selected volunteers with chronic myofascial pain (over 6 months) 4. Randomly selected volunteers with radicular pain due to C/TH and L/S discopathy
Exclusion criteria
Exclusion criteria: Exclusion from the study will occur in the case of persons, treatment of injury: 1. Musculoskeletal injuries at the place of therapy not earlier than 3 months 2. Damage or unspecified skin lesions in the tissue area where measurements and therapeutic methods will be performed (DN and physical medicine). 3. Pregnant women 4. Fear of needles 5. Extreme fatigue 6. Haemophilia 7. Active infection 8. At the express request of the volunteer 9. Cancer patients 10. Epilepsy patients 11. Nickel allergy Exclusion from the study may occur at any time during the experiment at the request of the participant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following basic outcome parameters will be assessed at rest (before the intervention), during the intervention (real-time) immediately after the intervention, 1 h after the intervention, and after 24 and 48 h, 7, 14 days, and 1, 2, and 3 months: 1. Muscle tension (T [Hz]) measured using the Myoton device (Myoton AS, Myoton Ltd, Estonia 2021) 2. Flexibility (E [arb- relative arbitrary unit]) measured using the Myoton device (Myoton AS, Myoton Ltd, Estonia 2021) 3. Maximum isometric force (Fmax [kgf]) measured using an electronic dynamometer (Kinvent Froce, France 2021) 4. Reactive Strength Index (RSI [ms-1]) measured using the Force Decks measuring platform (Vald Performance, Australia) 5. Muscle pennation angle and thickness (PA- [%]) measured using an ultrasound device (Sonoscape P20, China 2022) 6. Transcutaneous electromyographic examination measured using an EMG device (Deymed TruScan, 2022) 7. Assessment of the center of gravity [cm2] measured using a stabilometry platform with a pedobarograph MPS (France, 2019) 8. Pupillometric assessment of pupil dilation response [mm2] measured using an electronic pupilometer (Optol Techniology, Polska 2020) 9. Heart rate variability (HRV) measurement (HRV) measured using HUAWEI WATCH D2 smartwatch (China, 2023) | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measures will be assessed at rest (before the intervention), during the intervention (real-time) immediately after the intervention, 1 h after the intervention, and after 24 and 48 h, 7, 14 days, and 1, 2, and 3 months: 1. Muscle bundle length measured using ultrasound imaging 2. Subjective level measured using the Borga scale questionnaire 3. Perfusion parameters (ABI brachial index, AOP occlusive pressure, TR, BZ, zero index and BZ/RF resting flowmeter) measured using a perfusion monitoring device (e.g. Doppler laser flowmeter) 4. Level of serum catecholamines, creatine kinase and lactate measured using a blood sample test from an antecubital vein 10 ml max | — |
Countries
Poland, Portugal, Ukraine
Contacts
Public ContactAnna Lenzcewska
Outcome results
None listed